Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study

BACKGROUND: Adjuvant tamoxifen therapy approximately halves the risk of estrogen receptor positive breast cancer recurrence, but many women do not respond to therapy. Observational studies nested in clinical trial populations suggest that overexpression or nuclear localization of p21-activated kinas...

Full description

Saved in:
Bibliographic Details
Published in:Acta Oncol
Main Authors: Ahern, Thomas P., Cronin-Fenton, Deirdre P., Lash, Timothy L., Sørensen, Henrik Toft, Ording, Anne Gulbech, Hamilton-Dutoit, Stephen J., Hellberg, Ylva
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943575/
https://ncbi.nlm.nih.gov/pubmed/27056567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/0284186X.2016.1150606
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items